Whittier Trust’s Cytokinetics CYTK Stock Holding History

Whittier Trust’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-59	Closed	-$3.81K	–	1360
2025 Q4	$3.81K	Hold	59	–	–	﹤0.01%	1252
2025 Q3	$3.36K	Buy	+59	New	+$2.43K	﹤0.01%	1263

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Whittier Trust's CYTK Position: Q1 2026 in Review

Whittier Trust sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 59 shares — an estimated $3.81K sold.

Whittier Trust first reported a position in CYTK in Q3 2025 and held it in 2 quarters. The position peaked at $3.81K in Q4 2025. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Whittier Trust reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Whittier Trust sold 59 Cytokinetics shares in Q1 2026, an estimated $3.81K.
Whittier Trust first reported a position in Cytokinetics in Q3 2025 and held it in 2 quarters.
Whittier Trust's Cytokinetics position peaked at $3.81K in Q4 2025.
440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Whittier Trust's 13F filing for Q1 2026, filed 28 Apr 2026.